Article Sidebar

pdf
Date Published: 17/10/2024
Abstract Views: 0
Views pdf: 0
DOI: https://doi.org/10.51298/vmj.v543i2.11383
Issue
Vol. 543 No. 2 (2024)
Section
Các bài báo
How to Cite
Nguyễn, T. L., Lê, T. Đức, & Lê, T. Y. (2024). THE EFFECTIVENESS OF ENDOCRINE COMBINED WITH CDK4/6 INHIBITORS IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE STAGE IV DE NOVO BREAST CANCER. Vietnam Medical Journal, 543(2). https://doi.org/10.51298/vmj.v543i2.11383

THE EFFECTIVENESS OF ENDOCRINE COMBINED WITH CDK4/6 INHIBITORS IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE STAGE IV DE NOVO BREAST CANCER

Thị Lan Nguyễn, Thanh Đức Lê, Thị Yến Lê

Main Article Content

Abstract

Objectives: To evaluate the effectiveness of endocrine combined with CDK4/6 inhibitors in patients with hormone receptor-positive, HER2-negative de novo breast cancer (stage IV). Patients and methods: A retrospective and prospective descriptive study on 48 patients diagnosed with hormone receptor-positive, HER2-negative de novo breast cancer at K Hospital from January 2020 to February 2024. Result: The mean age was 56,0 years. The most common metastatic sites were bone, lympho node, lung and liver, respectively, accounting for 70,8%, 41,7%, 35,4% and 25%. The overall response rate of the regimen was 77,1%. The complete response rate was 2,1%, the partial response rate was 75% and 10,4% of the patients were stable. The clinical benefit rate was 87,5%. The median progression-free survival was 26 months. Conclusion: Endocrine combined with CDK4/6 inhibitors is effective inachieving high response rates and progression-free survival for patients with hormone receptor-positive, HER2-negative de novo breast cancer. This regimens should be more widely used in clinical practice.

Article Details

Keywords

de novo - metastatic breast cancer, hormone receptor-positive, HER2-negative, CDK4/6.

References

1. Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 74(3), 229-263.
2. Maaren MC van, Munck L de, Strobbe LJA, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer. 2019;144(2):263-272.
3. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925
4. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptorpositive,HER2-negative advanced breast cancer. Ann Oncol 2018; 29: 1541
5. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–24.
6. Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–16.
7. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(20):3271-3277.
8. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638-2645.
9. Begum N, Mehmood T. Literature review of visceral and non-visceral metastatic breast cancer. Ann Oncol. 2017;28:x32.
10. Lu, Yen-Shen et al. “Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.” Journal of clinical oncology: official journal of the American Society of Clinical Oncology, JCO2400144. 21 May. 2024, doi:10.1200/JCO.24.00144